✨ Free AI Report
BridgeBio Pharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research BridgeBio Pharma, Inc.
Company Research

BridgeBio Pharma, Inc.: Business Overview, Financials & Competitive Analysis

BridgeBio Pharma, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). De-risked pipeline with strong commercial execution on Attruby and multiple near-term approval catalysts position BridgeBio for substantial growth if execution succeeds despite ongoing cash burn challenges. Recent positive Phase 3 PROPEL 3 results for infigratinib in achondroplasia demonstrated statistically significant gains with a favorable safety profile, and infigratinib achieved.

What is BridgeBio Pharma, Inc.'s industry? BridgeBio Pharma, Inc. (bridgebio.com) operates in Biotechnology - Genetic Medicine & Rare Diseases. AskCyborg classifies BridgeBio Pharma, Inc. under Biotechnology - Genetic Medicine & Rare Diseases in its company registry.

BridgeBio exists to develop transformative medicines for genetic conditions, addressing the fact that millions of people worldwide living with genetic conditions lack treatment options, often because drug development ...

7/ 10Strong

Cyborg Score thesis

De-risked pipeline with strong commercial execution on Attruby and multiple near-term approval catalysts position BridgeBio for...

Read the full analyst-debate transcript →
Industry Biotechnology - Genetic Medicine & Rare Diseases
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest BridgeBio Pharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for BridgeBio Pharma, Inc.

AskCyborg analysts argue the bull and bear cases for BridgeBio Pharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BridgeBio Pharma, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

BridgeBio Pharma, Inc. Overview

Pro stress-test →

BridgeBio exists to develop transformative medicines for genetic conditions, addressing the fact that millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. The company combines commercial momentum with a robust late-stage pipeline positioned to drive significant growth through 2026 and beyond.

Strategic Profile

Pro stress-test →

BridgeBio is advancing its commercial strategy for Attruby and aims to double its patient reach by 2026, reflecting the effectiveness of its decentralized model in driving meaningful healthcare solutions. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy.

Competitive Landscape

Pro stress-test →

BridgeBio competes in genetic disease treatment space with 93 identified competitors including IVERIC bio and other biotechnology firms. As a rare disease-focused biopharmaceutical company with Attruby as its commercial anchor, BridgeBio differentiates through targeted genetic medicine development and emerging clinical proof-of-concept across multiple rare indications. Success will depend on execution against larger pharma players and specialized rare disease developers.

Industry Context

BridgeBio Pharma, Inc. operates in Biotechnology - Genetic Medicine & Rare Diseases.

Key facts

Founded: 2015 · Headquarters: Palo Alto, US · Revenue: $362.4M · Market cap: $15.2B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on BridgeBio Pharma, Inc..

  • February 2026 Phase 3 achondroplasia data breakthrough: infigratinib achieved record annualized height velocity gains with approvals expected H2 2026
  • Attruby dominance in ATTR-CM with 6,629 patient prescriptions by year-end 2025 and $362.4 million 2025 revenue drives commercial base
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Positive Phase 3 PROPEL 3 topline data for infigratinib in achondroplasia with highest reported height velocity gains
  • January 2026$550 million convertible senior notes offering completed; full-year 2025 Attruby revenue reached $362.4 million
  • +1 moreTrack every material event for BridgeBio Pharma, Inc. as it happens. Explore monitoring →
Get alerted when BridgeBio Pharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

AmgenLarge pharma with rare disease focus and skeletal dysplasia research→AlnylamRNA interference therapies for genetic diseases→Arrowhead PharmaceuticalsGenetic disease therapeutics→InvitaeGenetic testing and counseling for rare conditions→

Compare BridgeBio Pharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BridgeBio Pharma, Inc. operates in Biotechnology - Genetic Medicine & Rare Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Genetic Medicine & Rare Diseases research →
NEW · MCP server

Ask your AI assistant about BridgeBio Pharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BridgeBio Pharma, Inc. and its top competitor on Cyborg Score”
“What did BridgeBio Pharma, Inc. do this quarter?”
“Is BridgeBio Pharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does BridgeBio Pharma, Inc. do?+
BridgeBio exists to develop transformative medicines for genetic conditions, addressing the fact that millions of people worldwide living with genetic conditions lack treatment options, often because drug development ...
What is BridgeBio Pharma, Inc.'s Cyborg Score?+
BridgeBio Pharma, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BridgeBio Pharma, Inc.'s main competitors?+
Named competitors include Amgen, Alnylam, Arrowhead Pharmaceuticals, Invitae. The full competitive landscape is in the AskCyborg report.
How can I get the full BridgeBio Pharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BridgeBio Pharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BridgeBio Pharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Genetic Medicine & Rare Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Amgen Inc.